COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--Spectranetics Corporation (Nasdaq: SPNC) today reported financial results for the quarter ended March 31, 2009. Revenue for the first quarter of 2009 was $27.3 million, up 15% compared with revenue of $23.8 million for the first quarter of 2008. On a constant currency basis, revenue increased 16% compared with the first quarter of last year. Vascular intervention revenue rose 11% to $15.3 million, lead management revenue increased 29% to $8.2 million, laser revenue declined 12% to $1.5 million, and service and other revenue increased 14% to $2.4 million, all compared with the first quarter of 2008. Vascular intervention sales include three product lines -- atherectomy, which decreased 12%; crossing solutions, which increased 35%; and thrombectomy, which totaled $1.4 million of sales of QuickCat™ and ThromCat® products acquired from Kensey Nash Corporation (Nasdaq: KNSY) on May 31, 2008.
